top of page

Latest News

22.7.25

Prognostic implications of splenomegaly in BCMA-directed CAR T-Cell therapy for relapsed myeloma

New CERTAINTY-supported publication identifies spleen size as a prognostic marker in CAR T cell treatment

Prognostic implications of splenomegaly in BCMA-directed CAR T-Cell therapy for relapsed myeloma

8.7.25

HZDR joins the CERTAINTY consortium

A seamless transition of expertise ensures continued progress in stakeholder engagement and socio-economic research

HZDR joins the CERTAINTY consortium

3.7.25

Virtual twins for personalised CAR T-cell therapy in myeloma

New article highlights CERTAINTY’s approach to advancing personalised treatment

Virtual twins for personalised CAR T-cell therapy in myeloma
Key visuals (2).png

© Artur - stock.adobe.com / Fraunhofer IZI

For further information on the CERTAINTY project, feel free to contact us through email or keep up with our latest updates by following our social media channels.  

 

Email: info@certainty-virtualtwin.eu

Funded by the European Union Logo

This project was funded by the European Union under Grant Agreement number 101136379. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the Health and Digital Executive Agency. Neither the European Union nor the granting authority can be held responsible for them.

© 2024 by Collaborate Project Management.

  • LinkedIn
  • Youtube
bottom of page